Cara Therapeutics Inc
NASDAQ:TVRD
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Cara Therapeutics Inc
NASDAQ:CARA
|
83.4m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
596.5B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
293B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
249.7B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
240.5B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
307.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.9B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Cara Therapeutics Inc
Glance View
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 84 full-time employees. The company went IPO on 2014-01-31. The firm is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The firm is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates. The firm also initiated a pharmacokinetic safety trial of multiple doses of Oral CR845 in hemodialysis patients to define bioequivalent tablet strengths to inform its ability to develop an oral tablet formulation for moderate-to-severe uremic pruritus. CR701 is a peripherally restricted, mixed-CB1/CB2 receptor agonist that selectively interacts with these cannabinoid receptor subtypes, with no off-target activities.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Cara Therapeutics Inc is 91.3%, which is above its 3-year median of 74.7%.
Over the last 3 years, Cara Therapeutics Inc’s Gross Margin has increased from 10.4% to 91.3%. During this period, it reached a low of 10.4% on Mar 31, 2022 and a high of 91.3% on Jan 31, 2025.
